The Allogeneic Future with Poseida's Kristin Yarema, Ph.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. Dr. Yarema is the newly-appointed CEO at Poseida Therapeutics, a company we first covered with founding CEO Eric Ostertag, Ph.D. On this episode of the Business of Biotech, we'll learn about Dr. Yarema, how she earned the company's reins, how Poseida is positioning itself to crack the allogeneic CAR T code, and how strategic collaborations with the likes of Astellas and Roche are fueling the effort.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

فصول

1. The Allogeneic Future with Poseida's Kristin Yarema, Ph.D. (00:00:00)

2. CEO Transition From Consulting to Biotech (00:00:04)

3. Transitioning From Big Pharma to Biotech (00:15:46)

4. CEO Career Progression and Company Transition (00:30:35)

5. Scientific Collaboration in Biotech Industry (00:45:35)

6. Advancing Gene Therapy in Biotech (00:59:11)